Kedi ve Köpeklerde Hematolojik Aciller
Özet
Hematolojik aciller, kedi ve köpeklerde yaşamı tehdit eden, hızlı tanı ve acil tedavi gerektiren klinik tablolar olup hematopoetik, hemostatik ve fibrinolitik sistemlerin bozulması sonucunda gelişir. Bu bölümde hematolojik acillerin patofizyolojisi, klinik bulguları, tanısal yaklaşımları ve güncel tedavi yöntemleri kanıta dayalı bilgiler doğrultusunda ele alınmıştır. Hiperkalsemi, hiperlökositozis ve lökostazis, nötropenik ateş ve septik şok, kan transfüzyonu reaksiyonları, dissemine intravasküler koagülopati, anemi, trombositopeni ve tümör lizis sendromu gibi yaşamı tehdit eden hematolojik tablolar ayrıntılı olarak değerlendirilmiştir. Bu hastalıkların erken tanınmasının, uygun laboratuvar değerlendirmelerinin yapılmasının ve altta yatan nedenin hızla belirlenerek hedefe yönelik tedavinin başlanmasının mortaliteyi azaltmada temel öneme sahip olduğu vurgulanmıştır. Ayrıca yoğun bakım desteği, sıvı tedavisi, kan ve kan ürünü transfüzyonları, antimikrobiyal tedaviler, antikoagülan uygulamalar ve destekleyici bakım protokolleri güncel yaklaşımlar doğrultusunda açıklanmıştır. Hastaların yakın monitörizasyonu, organ perfüzyonunun korunması ve komplikasyonların erken yönetimi başarılı klinik sonuçların elde edilmesinde kritik rol oynamaktadır. Bu bölüm, kedi ve köpeklerde hematolojik acillerin tanı ve tedavisinde veteriner hekimlere sistematik, güncel ve klinik uygulamaya yönelik kapsamlı bir rehber sunmayı amaçlamaktadır.
Referanslar
Asonitis N, Angelousi A, Zafeiris C, Lambrou GI, Dontas I, Kassi E. Diagnosis, pathophysiology and management of hypercalcemia in malignancy: a review of the literature. Horm Metab Res. 2019;51(12):770-8.
Walker MD, Shane E. Hypercalcemia: a review. JAMA. 2022;328(16):1624-36.
Donald DM, Drake MT, Crowley RK. Treatment of hypercalcaemia of malignancy in adults. Clin Med (Lond). 2023;23(5):503.
Akirov A, Gorshtein A, Shraga-Slutzky I, Shimon I. Calcium levels on admission and before discharge are associated with mortality risk in hospitalized patients. Endocrine. 2017;57(2):344-51.
Gupta S, Rastogi A, Singh P, Chophy A, Roushan R, Krishnan AS, et al. Treatment outcomes and survival in hypercalcemia of malignancy: a grave metabolic emergency. Cureus. 2023;15(3):e35783.
Bao L, Wang Y, Lu M, Chu B, Shi L, Gao S, et al. Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients. Cancer Med. 2020;9(23):8962-71.
Cafforio P, Savonarola A, Stucci S, De Matteo M, Tucci M, Brunetti AE, et al. PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression. J Bone Miner Res. 2014;29(1):55-66.
Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y. Macrophage inflammatory protein-1α induces hypercalcemia in adult T-cell leukemia. J Bone Miner Res. 2004;19(7):1105-11.
Hewison M, Kantorovich V, Liker HR, Van Herle AJ, Cohan P, Zehnder D, et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res. 2003;18(3):579-82.
Noguchi M, Oshimi K. Extensive bone marrow necrosis and symptomatic hypercalcemia in B-cell blastic transformation of chronic myeloid leukemia: report of a case and review of the literature. Acta Haematol. 2007;118(2):111-6.
Gould Rothberg BE, Quest TE, Yeung SJ, Pelosof LC, Gerber DE, Seltzer JA, et al. Oncologic emergencies and urgencies: a comprehensive review. CA Cancer J Clin. 2022;72(6):570-93.
Yee AJ, Raje NS. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging. 2012;7:331-8.
Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments? Cells. 2020;9(10):2310.
Blackburn LM, Brown S, Munyon A, Orovets M. Leukostasis: management to prevent crisis in acute leukemia. Clin J Oncol Nurs. 2017;21(5):E267-E271.
Zhang D, Zhu Y, Jin Y, Kaweme NM, Dong Y. Leukapheresis and hyperleukocytosis, past and future. Int J Gen Med. 2021;14:3457-67.
Duminuco A, Nardo A, Giuffrida G, Leotta S, Markovic U, Giallongo C, et al. Myelofibrosis and survival prognostic models: a journey between past and future. J Clin Med. 2023;12(6):2188.
Ali AM, Mirrakhimov AE, Abboud CN, Cashen AF. Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest. Hematol Oncol. 2016;34(2):69-78.
Bug G, Anargyrou K, Tonn T, Bialleck H, Seifried E, Hoelzer D, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007;47(10):1843-50.
Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia: a systematic review and meta-analysis. Transfusion. 2020;60(10):2360-9.
Farid KMN, Sauer T, Schmitt M, Müller-Tidow C, Schmitt A. Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis. Cancers (Basel). 2023;16(1):58.
Duminuco A, Maugeri C, Parisi M, Mauro E, Fiumara PF, Randazzo V, et al. Target therapy for extramedullary relapse of FLT3-ITD acute myeloid leukemia: emerging data from the field. Cancers (Basel). 2022;14(9):2186.
Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia on short- and long-term clinical outcomes: a large retrospective multicenter international study. Leukemia. 2020;34(12):3149-60.
Alwood AJ, Brainard BM, LaFond E, et al. Postoperative pulmonary complications in dogs undergoing laparotomy: frequency, characterization and disease-related risk factors. J Vet Emerg Crit Care. 2006;16:176-183.
Ralphs SC, Jessen CR, Lipowitz AJ. Risk factors for leakage following intestinal anastomosis in dogs and cats: 115 cases (1991-2000). J Am Vet Med Assoc. 2003;223:73-77.
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-e93.
Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53:798-806.
Duminuco A, Scarso S, Cupri A, Parrinello NL, Villari L, Scuderi G, et al. Leishmania infection during ruxolitinib treatment: the cytokines-based immune response in the setting of immunocompromised patients. J Clin Med. 2023;12:578.
Palumbo GA, Cambria D, La Spina E, Duminuco A, Laneri A, Longo A, et al. Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. Front Oncol. 2023;13:1117815.
Duminuco A, Nardo A, Orofino A, Giunta G, Conticello C, Del Fabro V, et al. Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in hematological conditions. Cancer. 2024;130:41-50.
Almac E, Ince C. The impact of storage on red cell function in blood transfusion. Best Pract Res Clin Anaesthesiol. 2007;21:195-208.
Kor DJ, Van Buskirk CM, Gajic O. Red blood cell storage lesion. Bosn J Basic Med Sci. 2009;9(Suppl 1):21-27.
Lelubre C, Piagnerelli M, Vincent JL. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion. 2009;49:1384-1394.
Giger U. Regenerative anemias caused by blood loss or hemolysis. In: Ettinger SJ, Feldman EC, editors. Textbook of Veterinary Internal Medicine. 6th ed. St. Louis: Elsevier Saunders; 2005. p. 1886-1907.
Miller MD, Lunn KF. Diagnostic use of cytologic examination of bone marrow from dogs with thrombocytopenia: 58 cases (1994-2004). J Am Vet Med Assoc. 2007;231:1540-1544.
